Please Wait...

Retention

Engage Patients

Patient retention depends on patient engagement – and we are experts in the field, having earned 16 awards for the best-designed patient recruitment and retention materials.

We have discovered that the most effective retention strategies begin at the first patient encounter. We customize a program for each study designed to keep patients enrolled until completion, ensuring the study’s statistical power and protecting your investment.

Our patient engagement programs include:

  • Medical symposia and events to educate patients and caregivers
  • Patient advocacy partnerships to clearly communicate study information to patients and caregivers
  • Customized print and digital materials to counteract any retention issues that arise

ADDITIONAL RESOURCES

Patient Recruitment and Retention

Download Brochure

Alzheimer's Disease

Download Case Study

Pediatric Schizophrenia

Download Case Study

Chronic Pain Study

Download Case Study

RAPSODI Study

Download Case Study

ALLEGRO Study

Download Case Study

The ALFACHIN Study

Download Case Study

Childhood Depression Study

Download Case Study

Nerve Pain Study

Download Case Study

Global Clinical Research

Download Brochure

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (Yesterday)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (2 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (4 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (4 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (4 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (4 days ago)

Latest Blogs: